Study protocol and statistical plan for the ICRAKI trial: Intermittent haemodialysis versus continuous renal replacement therapy for severe acute kidney injury in critically ill patients.

Fiche publication

Date publication

juin 2025

Journal

Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Gaudry S, Boubaya M, Louis G, Chaïbi K, Mégarbane B, Bohe J, Desgrouas M, Gele-Decaudin G, Joseph A, de Montmollin E, Camus C, De Prost N, Bailly P, Jaber S, Chudeau N, Lambour A, Robine A, La Combe B, Kimmoun A, Chevrel G, Argaud L, Nicolas J, Thiery G, Faguer S, Jozwiak M, Ricard JD, Contou D, Marzouk M, Chousterman B, Cadiet J, Bureau C, Zaleski ID, Rossignol P, Quenot JP, Queyrat CB, Dreyfuss D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40458742

Résumé

The effect of intermittent haemodialysis (IHD) continuous renal replacement therapy (CRRT) on mortality and/or renal function recovery in adults with acute kidney injury (AKI) and a recognised indication for renal replacement therapy (RRT) remains controversial.